VTGN

#4758
Vistagen Therapeutics, Inc. - Common Stock
0.2 4 USD
+0.04%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.24
0.24
Jahresspanne
0.20
0.80
Tagesänderung
+4.35%
Monatliche Änderung
+9.09%
6 month change
-53.41%
Jahresänderung
-53.41%
Vorheriger Schlusskurs
0.2 4
Open
0.2 4
Tief
0.2 4
High
0.2 4
Volumen
14
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K

Vistagen Therapeutics, Inc. current report, Q2 FY2026

Vistagen Therapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. (VTGN) on May 18, 2026. The filing discloses the appointment of a new executive officer and related compensatory arrangements.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:

  • Base Salary: $425,000 annually.
  • Signing Bonus: $50,000 total (50% paid on effective date, 50% after six months).
  • Target Cash Bonus: 45% of annual base salary, subject to performance goals.
  • Equity Grant: Options to purchase 150,000 shares of common stock.
  • Option Exercise Price: $0.5955 per share (closing price on May 18, 2026).
  • Option Vesting: Begins one year after the effective date; vests monthly over 36 months (fully vested on the fourth anniversary).

Material Changes

The primary material change is the appointment of Angel S. Angelov, M.D., MBA, as Chief Medical Officer (CMO) effective May 18, 2026. Dr. Angelov joins from Theranica, where he served as CMO from October 2024 to May 2026. He brings prior experience from Karuna Therapeutics (Bristol Myers Squibb), Neurocrine Biosciences, and other major pharmaceutical firms.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or discussion of general business risks. The only disclosed contingency relates to the equity grant, which is contingent upon Dr. Angelov's continued service to the Company. An Indemnification Agreement was also executed to protect Dr. Angelov against liabilities arising from his service.

Key Facts for Investor Verification

  • Verify the impact of the new CMO's appointment on the company's clinical development pipeline.
  • Confirm the total dilution impact of the 150,000 share option grant relative to the current share count.
  • Review the specific performance goals required to achieve the 45% target cash bonus.
  • Monitor the vesting schedule to understand future compensation obligations.

Nachrichten